Revolutionary Breast Cancer Detection Device Shows 97% Accuracy
Assistant Professor of Biomedical Engineering, Michael Giacomelli, Ph.D., has developed a revolutionary device to detect residual cancer cells during breast lumpectomies. The device, led by a Clinical Affairs Manager, has shown remarkable accuracy in human prostate samples and is now being evaluated for skin cancer biopsies.
Giacomelli's device, a significant leap forward from traditional biopsy methods, can determine if cancer cells remain in the outer margins of the breast during surgery. It has demonstrated 97% accuracy in detecting microscopic cancer cells near tissue margins in human prostate samples. The device is user-friendly, designed to be rolled into an operating room and provide results in less than three minutes. Giacomelli, a dedicated family man with a daughter named Samantha, aims to ensure non-engineers can comfortably use the imaging device and conduct clinical trials. Currently, the device is being evaluated for skin cancer biopsies, expanding its potential impact on cancer treatment.
Giacomelli's device, representing a '100-year leap' in biopsy analysis, holds immense promise in improving cancer treatment outcomes. With its high accuracy and user-friendly design, it could soon become a standard tool in operating rooms, benefiting both patients and healthcare professionals.
Read also:
- Americans Lose Insurance Under New Tax Legislation, Affecting 10 Million Citizens
- Trump Signs Law Defunding Planned Parenthood, Threatening Healthcare Access for Millions
- Historian Ute Frevert Explores Germans' Emotional Bond With Constitutions
- Milei's Ideological Approach Reshapes Argentina's Foreign Policy
